Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Moberg Pharma AB (publ)    MOB   SE0003613090

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Moberg Pharma publ : NOMINATION COMMITTEE APPOINTED

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 08:31am CET

STOCKHOLM, November 10th, 2017 - In accordance with the resolution of the Annual General Meeting on May 18, 2017, the Chairman of the Board has contacted the company's three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company's three largest shareholders or group of shareholders have wished to appoint such representative, the forth largest shareholder/group of shareholders have been invited to appoint one representative and so on until the Nomination Committee now comprises of four members, in accordance with the resolution of the Annual General Meeting on May 18.

Moberg Pharma's Nomination Committee ahead of the 2018 Annual General Meeting comprises: 

·  Thomas Eklund, Chairman of the Board
·  Gillis Cullin, appointed by Östersjöstiftelsen
·  Fredrik Persson, appointed by Zimbrine Holding
·  Anders Rodebjer, appointed by Wolco Invest

Together, the Nomination Committee represents 25.3 percent of the shares in Moberg Pharma as of September 30, 2017.

The Nomination Committee shall submit proposals for resolution by the 2018 Annual General Meeting pertaining to the election of Chairman of the Board, fees and composition of the Board, auditors' fees and the election of auditors.

The 2018 Annual General Meeting will be held in Stockholm on May 15.

Shareholders wishing to submit proposals to Moberg Pharma's Nomination Committee can do so by e-mail to [email protected] by 31 December 2017.

About this information
This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 a.m. CET on November 10th, 2017

For additional information, please contact:
Peter Wolpert, CEO, Phone: +1 908 432 22 03 (US), +46 707 35 71 35 (SE), E-mail: [email protected]
Anna Ljung, CFO, Phone: +46 707 66 60 30, E-mail: [email protected]

About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company's portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, New Skin®, Dermoplast®and Domeboro®. Kerasal Nail®(Emtrix®, Zanmira®or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two assets in late-stage clinical development, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company's shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).

http://news.cision.com/moberg-pharma/r/moberg-pharma-s-nomination-committee-appointed,c2387146

http://mb.cision.com/Main/1662/2387146/749074.pdf

(c) 2017 Cision. All rights reserved., source Press Releases - English

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MOBERG PHARMA AB (PUBL)
11/13 MOBERG PHARMA AB : interim report January - September 2017
11/10 MOBERG PHARMA PUBL : Nomination committee appointed
11/10 MOBERG PHARMA PUBL : Nomination committee appointed
11/08MOBERG PHARMA AB (PUBL) : quaterly earnings release
11/08 MOBERG PHARMA PUBL : provides update on timeline for MOB-015
11/06 MOBERG PHARMA PUBL : report for the third quarter to be published on November 13..
11/06 MOBERG PHARMA PUBL : report for the third quarter to be published on November 13..
10/19 MOBERG PHARMA PUBL : Patent Issued for Pharmaceutical Composition for the Treatm..
09/22 MOBERG PHARMA PUBL : Addition to Moberg Pharma´s management team
09/22 MOBERG PHARMA PUBL : Addition to Moberg Pharma's management team
More news
News from SeekingAlpha
09/08 Moberg Pharma (MBGRF) Presents At Pareto Securities' 8th Annual Health Care S..
Financials ( SEK)
Sales 2017 437 M
EBIT 2017 39,1 M
Net income 2017 1,10 M
Debt 2017 494 M
Yield 2017 -
P/E ratio 2017 115,12
P/E ratio 2018 101,43
EV / Sales 2017 2,27x
EV / Sales 2018 2,27x
Capitalization 495 M
Chart MOBERG PHARMA AB (PUBL)
Duration : Period :
Moberg Pharma AB (publ) Technical Analysis Chart | MOB | SE0003613090 | 4-Traders
Technical analysis trends MOBERG PHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus
Number of Analysts 1
Average target price 56,9  SEK
Spread / Average Target 100%
EPS Revisions
Managers
NameTitle
Peter Gunnar Maurits Wolpert Chief Executive Officer
Thomas Lennart Eklund Chairman
Anna Ljung Chief Financial Officer
Kjell Rensfeldt Chief Medical Officer, VP-Research & Development
Torbjörn Mattias Koivisto Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MOBERG PHARMA AB (PUBL)-49.12%59
JOHNSON & JOHNSON19.78%370 740
NOVARTIS11.20%219 321
PFIZER8.90%210 830
ROCHE HOLDING LTD.-1.55%200 193
MERCK AND COMPANY-6.23%150 550